Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Frequency moving to test agents with remyelination potential

Frequency TherapeuticsĀ announced that it is shifting its focus to advancing small molecules that aim to restore myelin, the protective cover around nerve fibers that is damaged and lost with multiple sclerosis (MS). This decision follows the failure of an investigative treatment for people with acquired hearing loss to…

Crowdfunding Campaign Launched for MS, Other Clinical Programs

FibroBiologics hasĀ launched an online crowdfunding campaign to support the development of potential therapies in the companyā€™s pipeline and advance its clinical programs in multiple sclerosis (MS) and other diseases. The campaign was begun in collaboration with StartEngine, an equity crowdfunding platform that facilitates investments in startup companies.

Aubagio Significantly Lowers Plasma NfL Levels in TERIKIDS Trial

Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). Thatā€™s according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…

Newer Neurologic Therapies Costly, Less Likely to Be Used

Fewer than 1 in 5 people living with multiple sclerosis (MS) or 10 other neurological conditions in the U.S. are on new-to-market medications. Thatā€™s according to a large data study funded by the American Academy of Neurology, which also linked more recently available treatments ā€” those approved in the…

How Nasal Foralumab Affects Healthy Immune System: Study

Foralumab nasal spray, an experimental therapy by Tiziana Life Sciences thatā€™s being tested for multiple sclerosis and other autoimmune and nervous system diseases, was found to be safe and able to modulate the immune system in healthy volunteers, a study has found. Researchers failed to detect antibodies…